Search Results

You are looking at 1 - 10 of 58 items for :

  • "differentiated thyroid carcinoma" x
  • Refine by Access: All content x
Clear All
Open access

S C Clement, W E Visser, C A Lebbink, D Albano, H L Claahsen-van der Grinten, A Czarniecka, R P Dias, M P Dierselhuis, I Dzivite-Krisane, R Elisei, A Garcia-Burillo, L Izatt, C Kanaka-Gantenbein, H Krude, L Lamartina, K Lorenz, M Luster, R Navardauskaitė, M Negre Busó, K Newbold, R P Peeters, G Pellegriti, A Piccardo, A L Priego, A Redlich, L de Sanctis, M Sobrinho-Simões, A S P van Trotsenburg, F A Verburg, M Vriens, T P Links, S F Ahmed, and H M van Santen

Background Pediatric differentiated thyroid carcinoma (DTC) is a rare disease, although it is the most frequent endocrine malignancy in children, representing 2–4% of all pediatric malignancies. According to the Surveillance, Epidemiology, and

Open access

Alexander Heinzel, Dirk Müller, Hanneke M van Santen, Sarah C Clement, Arthur B Schneider, and Frederik A Verburg

-1375678 ) 13 Thies ED Tanase K Maeder U Luster M Buck AK Hanscheid H Reiners C Verburg FA . The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma

Open access

Keiko Ohkuwa, Kiminori Sugino, Mitsuji Nagahama, Wataru Kitagawa, Kenichi Matsuzu, Akifumi Suzuki, Chisato Tomoda, Kiyomi Hames, Junko Akaishi, Chie Masaki, and Koichi Ito

patients with DTC and is predominantly observed in the lungs and bone ( 3 , 4 , 5 , 6 ). When treating metastatic tumors of differentiated thyroid carcinoma, a favorable prognosis can be expected after radioactive iodine (RAI) therapy after total

Open access

Tiemo S Gerber, Arno Schad, Nils Hartmann, Erik Springer, Ulrich Zechner, and Thomas J Musholt

Introduction Poorly differentiated thyroid carcinoma (PDTC) represents an aggressive variant of thyroid cancer that predominantly arises from the differentiated variants of papillary and follicular thyroid carcinoma (PTC and FTC, respectively

Open access

Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim, and Erik K Alexander

2013 37 1599 – 1605 . ( doi:10.1007/s00268-013-2006-9 ). 23 Lee J Soh EY . Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors . Annals of Surgery 2010 251 114

Open access

Andrea Mazurat, Andrea Torroni, Jane Hendrickson-Rebizant, Harbinder Benning, Richard W Nason, and K Alok Pathak

Introduction Well-differentiated thyroid carcinoma (WDTC) represents a group of thyroid cancers that are associated with increasing incidence and excellent posttreatment outcome (1) . This group comprises different histological types, the most

Open access

Maria Luisa Garo, Désirée Deandreis, Alfredo Campennì, Alexis Vrachimis, Petra Petranovic Ovcaricek, and Luca Giovanella

) 22 Tang J Kong D Cui Q Wang K Zhang D Liao X Gong Y & Wu G . Racial disparities of differentiated thyroid carcinoma: clinical behavior, treatments, and long-term outcomes . World Journal of Surgical Oncology 2018 16 45 . ( https

Open access

Thera P Links, Trynke van der Boom, Wouter T Zandee, and Joop D Lefrandt

indicate that administration of TSH suppression therapy is associated with increased cardiovascular risk ( 36 , 37 ). Prevention of cardiovascular events in differentiated thyroid carcinoma The question arises which DTC patients are at risk of

Open access

Natalie Su-Jing Yap, Richard Maher, and Diana Louise Learoyd

Introduction Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy, of which the majority are papillary thyroid carcinoma (PTC). While prognosis is generally favourable, up to 20% of patients develop local or regional

Open access

Kim Magaly Pabst, Robert Seifert, Nader Hirmas, Martina Broecker-Preuss, Manuel Weber, Wolfgang Peter Fendler, Timo Bartel, Sarah Theurer, Ken Herrmann, and Rainer Görges

Current guidelines for differentiated thyroid carcinoma (DTC) ( 1 , 2 ) assign a crucial diagnostic importance to stimulated thyroglobulin (s-Tg) measurement 6–12 months after completion of primary therapy to predict a recurrence-free follow-up than in